Expects Pen-G production capacity to touch 10k metric tonnes in 12 months: Aurobindo Pharma

Aurobindo Pharma is set to boost Penicillin-G output to over 10,000 metric tonnes annually. Its China manufacturing facility is projected to reach EBITDA break-even this quarter. The company is also advancing its US operations and developing complex generics. These strategic moves aim for sustainable growth and improved profitability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sdLF4H2
via IFTTT

Read More

BahiaFarma, Biocon, Bionovis inks MoU in pharma sector

India and Brazil signed multiple Memoranda of Understanding (MoUs) during Brazilian President Lula da Silva's visit. Key agreements include a pact for developing a breast cancer medicine, cooperation in iron ore blending at Gangavaram Port, and R&D in strategic pharmaceutical ingredients. ApexBrasil and FICCI also agreed to boost trade and investment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PnhsZ48
via IFTTT

Read More

Quality Care India plans to invest Rs 600 crore to set up healthcare facility in Nagpur

Quality Care India Limited is set to invest Rs 600 crore in a new 350+ bed multi-speciality hospital in Nagpur. The facility, to be developed on Maha-Metro land near Kasturchand Park Metro Station, aims to strengthen healthcare infrastructure in Central India. This project, a public-private partnership, is expected to create over 1,500 jobs and enhance regional healthcare capacity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9QZqgoM
via IFTTT

Read More

Novartis exits India arm, ChrysCapital-led group buys 70.68% stake for ₹1,446 crore

Swiss drugmaker Novartis AG is selling its 70.68% stake in its Indian unit for Rs 1,446 crore to a consortium led by ChrysCapital. This divestment aligns with Novartis' strategy to become a pure-play innovative medicines company, while it maintains a significant presence in India through its wholly owned subsidiary.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0hWX6Y8
via IFTTT

Read More

Drugmakers flag concerns over blue-strip antibiotic labels

The government mandated a blue line on antibiotic packaging to curb misuse. However, pharmaceutical companies argue this will disrupt operations and finances. They believe the measure lacks scientific backing and global alignment. Industry associations are urging the government to withdraw the notification. Existing regulations already address antimicrobial resistance concerns.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GuhQOfs
via IFTTT

Read More

ChrysCapital, two others launch open offer for Novartis India

A consortium including WaveRise Investments, ChrysCapital, and Two Infinity Partners is set to acquire a significant stake in Novartis India. This move is part of Novartis's strategy to divest its stake. The transaction is expected to conclude in the third quarter of 2026. Novartis will continue its operations in India through Novartis Healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lQVLZwt
via IFTTT

Read More

Indian drugmaker Sai Life Sciences to boost headcount by about 20% amid global demand upswing

Sai Life Sciences will boost its workforce by over 700 employees next financial year. This expansion supports growing global demand for its services. The company is increasing capacity to meet this demand. New hires will focus on scientific, technical, and management roles. This move reflects a broader trend of global pharma companies expanding in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ExMusJk
via IFTTT

Read More

Thyroid, antibiotic drugs face fresh safety warnings after national review

New safety warnings are coming for two common medicines, doxycycline and carbimazole. Indian drug regulators have identified potential mental health side effects for doxycycline. Carbimazole will now carry stronger warnings about a rare but serious blood disorder. Manufacturers must update prescribing information. These changes aim to improve patient safety by highlighting important risks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/H09vWqY
via IFTTT

Read More

Zydus launches biosimilar for ophthalmic care

Zydus Lifesciences has introduced Anyra, its first indigenously developed biosimilar for the treatment of visual impairment in India. This innovative drug, akin to Aflibercept 2 mg, addresses vision loss resulting from diseases like diabetes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eCiGEwj
via IFTTT

Read More

Pharma firms asked for side-effects of common medicines

India's drug regulator has issued new safety warnings for common medicines. Doxycycline, an antibiotic, will now list side effects like anxiety and dizziness. Carbimazole, used for thyroid issues, will highlight the risk of a life-threatening condition called agranulocytosis. Manufacturers must update package inserts and promotional materials. These changes follow recommendations from pharmacovigilance experts to ensure patient safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QCPknbg
via IFTTT

Read More

Warburg Pincus talks in final lap to buy Integrace Health for Rs 1,200 crore

Integrace is currently owned by homegrown PE fund True North and Singapore sovereign investor Temasek Holdings. True North Fund VI LLP holds a 55.83% stake in Integrace, while Temasek arm V-Science Investments Pte owns 43.91%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t7hfmGZ
via IFTTT

Read More

Steroid abuse among gym-goers raises heart, liver risks; issue raised in Parliament

Young people are facing severe health issues due to steroids and unsafe supplements. Doctors report liver toxicity, infertility, and aggression. Heart specialists warn of life-threatening consequences like heart attacks. Mental health experts note links to depression and anxiety. The market for these substances requires stricter checks and greater awareness among youth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HaBfwyV
via IFTTT

Read More

Seeing with sound: AIIMS distributes AI-powered smart glasses to help visually impaired

AIIMS has equipped 53 visually impaired individuals with advanced AI-powered smart vision glasses, transforming their environments into audible guidance. This innovative project empowers both children and adults to navigate life with newfound independence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yZ6uDUx
via IFTTT

Read More

AI can address health inequities, but cannot replace human touch: Union MoS Health Anupriya Patel

Speaking at the AI Impact Summit in the national capital, Patel asserted that India's governance model positions AI as an enabler and force multiplier, bringing the country closer to the goals of inclusivity and health equity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3wjVESA
via IFTTT

Read More

29 vitamin-mineral FDC drugs under review for possible ban over 'irrational' tag

A looming ban on twenty-nine vitamin and mineral combination drugs has sparked a heated debate. Initially flagged as irrational by an expert panel in 2015, these products are now being re-evaluated by a specialized sub-committee. Before any final ruling, the companies will be given a chance to defend their products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eWhaIyb
via IFTTT

Read More

Lupin signs supply deal to launch antidepressant in Canada

Drug firm Lupin has partnered with Spektus Pharma. They will commercialise the antidepressant DeslaFlex in Canada. This collaboration combines Lupin's Canadian presence with Spektus's formulation expertise. It aims to offer patients more personalized care for Major Depressive Disorder. The deal strengthens Lupin's central nervous system portfolio. Lupin shares saw a slight increase on Monday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kMS69A4
via IFTTT

Read More

Alkem Labs' Chakan facility gets six observations in USFDA inspection, no data integrity issues

Alkem Laboratories announced its subsidiary Enzene Biosciences received a Form 483 from the USFDA. The inspection at the Chakan manufacturing unit resulted in six procedural observations. The company highlighted zero observations related to data integrity. Enzene is preparing its response to the USFDA within the given timeline. Corrective actions are also being initiated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uRrOng6
via IFTTT

Read More

Govt looks to provide access to AI resources to medical students: Official

The government plans to give medical students access to e-books and AI tools. This initiative will begin with 57 government medical colleges in smaller towns and rural areas. The aim is to improve students' skills by providing better access to digital and AI-powered learning materials. The program will gradually expand to include private colleges later.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PVv2AMH
via IFTTT

Read More

Adven Biotech says it's India's first homeopathic brand to get NABL certification

Adven Biotech achieves a significant milestone as India's first homeopathy brand to earn NABL certification. This accreditation underscores India's commitment to global healthcare standards in the Ayush sector. The certification validates Adven's quality control and testing laboratories, aligning with Prime Minister Modi's vision for Ayush. It aims to boost confidence and expand the global acceptance of Indian homeopathy.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zTj9iAE
via IFTTT

Read More

GST rejig marks key shift towards making cancer care affordable, AIIMS researchers says

AIIMS researchers highlight recent GST reforms, including tax exemptions on cancer drugs and medical equipment, aiming to make cancer care more affordable. Increased taxation on tobacco products is also noted as a positive step for public health and revenue generation for cancer initiatives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g7EB8Ql
via IFTTT

Read More

India becoming backbone of global clinical research

India has emerged as a key player in international clinical trials, showcasing resilience even in the face of global hurdles. With research and innovation on the rise, firms like Parexel recognize India's crucial contribution to ensuring consistent business operations. Instead of threats, artificial intelligence presents avenues for professionals to expand their roles and skillsets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZivtCy1
via IFTTT

Read More

Alkem Labs unit to buy up to 55% of Occlutech for $118 million

Alkem Laboratories is entering the advanced cardiovascular devices market. Its medical devices unit will acquire a significant stake in Switzerland's Occlutech Holding. This strategic move aims to access high-value global markets. The deal is expected to finalize by June 2026. Occlutech is a key player in Europe's minimally invasive cardiac implants.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QRcUVtm
via IFTTT

Read More

AIIMS Delhi first in country to announce launch of face transplant programme

AIIMS New Delhi has become the first hospital in India to introduce face transplantation, a complex reconstructive procedure for patients with severe facial deformities. The Department of Plastic, Reconstructive and Burns Surgery has begun creating a patient registry and is conducting specialised training, including a cadaveric workshop, with support from international expert Dr Indranil Sinha of Harvard Medical School.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zHdnsOB
via IFTTT

Read More

HUL turns ₹70 cr bet in Wellbeing Nutrition into ₹307 cr exit

Hindustan Unilever has divested its 19.8% stake in Wellbeing Nutrition to UVS Pharma for Rs 307 crore. This move comes after HUL's initial Rs 70 crore investment in 2022. The transaction, expected to conclude by March 2026, sees Wellbeing Nutrition valued at approximately Rs 1,600 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r7hxTCY
via IFTTT

Read More

Zydus settles US Mirabegron patent dispute with Astellas for $120 million

Zydus Lifesciences and its US subsidiary have settled patent litigation with Astellas Pharma over Astellas' Myrbetriq. Zydus will pay Astellas $120 million upfront and a per-unit licensing fee on generic Mirabegron sales until September 2027. This agreement resolves all disputes and allows Zydus to continue marketing its generic version in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u2lCe6r
via IFTTT

Read More

USV Pharma leads race to buy 85% stake in Wellbeing Nutrition at Rs 1,600 crore valuation

The Mumbai-based brand, owned by Nutritionlab, counts Hindustan Unilever and Fireside Ventures among its early backers. HUL and Fireside — holding 19.8% stake each — will exit with more than fourfold returns. Both invested in Wellbeing Nutrition about three years ago when the company was valued at about Rs 350 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8v4k2bP
via IFTTT

Read More

Trial by fire: Novelis may see bigger cash flow hit

In the wake of a second devastating fire at its Oswego facility, Novelis Inc. has revised its expectations dramatically, now forecasting a staggering impact on its free cash flow. Originally bracing for a loss of $550-650 million, the company is now looking at potential damages between $1.3-1.6 billion prior to insurance compensation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UL1XGcu
via IFTTT

Read More

Zydus Life cleared to sell life-saving cancer drug; SC tells Bristol Myers to map patents

The Supreme Court has provided Zydus Lifesciences with the go-ahead to launch its cancer drug biosimilar, countering efforts by Bristol Myers Squibb to halt its progress. The court has mandated that BMS verify how Zydus's product aligns with their patent claims, with options for BMS to request provisional support from the High Court following this analysis.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Az5Lho8
via IFTTT

Read More

Warburg-Mubadala leads race to buy majority in Soframycin maker

Exciting developments are afoot as Encube Ethicals, a key player in the pharma contract manufacturing sector, approaches a significant acquisition. The frontrunners, Warburg Pincus and Mubadala, are intensifying their bids, valuing the company at approximately ₹16,500 crore. This move underscores the burgeoning interest investors have in Indian CDMO companies, fueled by global supply chain shifts and evolving US policies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x2Wz09B
via IFTTT

Read More

French pharma giant Servier to invest €15 million to launch global single-pill platform 'GATINN' in India

French pharma group Servier is expanding in India with a €15 million investment to launch GATINN, a global platform for single pill combinations (SPCs) targeting cardiometabolic and venous diseases. The India-based hub will coordinate research, manufacturing, and exports to international markets, aiming to improve patient adherence by combining multiple drugs into a single daily dose.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ePsq5ZK
via IFTTT

Read More

IHH Healthcare, Fortis launch initiative to strengthen healthcare innovation ecosystem

IHH Healthcare, in partnership with Fortis Healthcare, is proud to introduce IHH Catalyst. This groundbreaking initiative is designed to fast-track the integration of innovative technology in healthcare across India. By empowering promising health-tech and med-tech startups to shift from concept to concrete implementation, IHH Catalyst aims to elevate patient care and optimize hospital processes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KRwBh2b
via IFTTT

Read More

AstraZeneca gets CDSCO nod to market cancer drug Imfinzi for additional indication

AstraZeneca Pharma India has secured approval from India's drug regulator for Durvalumab, marketed as Imfinzi. This new indication allows its use in treating advanced or recurrent endometrial cancer. The drug will be administered in combination with other therapies for initial treatment. Following this, Durvalumab will be used as maintenance therapy for specific patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kXT7w6P
via IFTTT

Read More

Lupin clears Mirabegron patent dispute with Astellas in $90 million deal, secures US sales continuity

Drugmaker Lupin has settled a patent infringement dispute with Astellas Pharma over its Mirabegron product for $90 million. The agreement includes a $75 million prepaid option payment and a per-unit license fee. This resolution allows Lupin to continue marketing Mirabegron in the U.S., removing a significant legal obstacle.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TxGzH5g
via IFTTT

Read More

Decide on Piramal's Dahej plant in a week: Supreme Court to Gujarat Pollution Control Board

The Supreme Court has issued a swift order for the Gujarat Pollution Control Board to review Piramal Pharma's appeal to reactivate its Dahej manufacturing site, which was closed due to serious allegations related to hazardous waste management. The firm sought interim relief but was turned down by the court.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uUl4syC
via IFTTT

Read More

Sampre Nutrition arm to set up facility in Egypt

Sampre Nutrition will expand its global reach with a new manufacturing unit in Egypt. Orascom Industrial Parks has approved land for food processing and confectionery. This facility will boost production and support international growth. The company recently partnered with Reliance Consumer Products. Sampre Nutrition saw a significant revenue increase in the first half of the year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Kn7VzqW
via IFTTT

Read More

Sun Pharma, Dr Reddy's & Lupin call for big push in drug innovation

Top Indian pharmaceutical leaders are urging a significant boost in research and development. They believe this focus on innovation is crucial for India to become a global biopharma manufacturing hub. Leaders from Sun Pharma, Cipla, Dr Reddy's Laboratories, and Lupin highlighted the need for greater investment and a shift towards developing novel drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qTCVJ6L
via IFTTT

Read More

India expected to see surge in Parkinson's disease, becoming 2nd-highest in 5 yrs: Experts at 6th International Annual Symposium-2026 in Kerala

India faces a surge in Parkinson's disease cases, potentially becoming second globally. Young-onset Parkinson's is a growing concern in Southeast Asia. Experts at a Kerala symposium highlighted the need for region-specific research and affordable treatments. Local manufacturing and international collaboration are key to expanding access to care for millions of patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ED1bohU
via IFTTT

Read More

Sun Pharma to stay disciplined on M&A, says Dilip Shanghvi

Sun Pharma plans a careful acquisition strategy. The company prioritizes organic growth to remain an attractive investment. Chairman Dilip Shanghvi highlighted a focus on innovative medicines in the US. Smaller acquisitions are being considered for emerging markets. The firm is also evaluating the biosimilar sector. This approach aims to strengthen long-term capabilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AgdF51Y
via IFTTT

Read More

Battle for cooking oil: Nutritionists reveal which oil is best and what separates one from another

The battle for cooking oil has been heating up — with everything from coconut, mustard and refined oils fighting for shelf space, while avocado oil puts in an appearance now. ET asks experts whether any one oil can ever triumph over others.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/06hLabo
via IFTTT

Read More

Strengthening the India-US medicines partnership important: IPA

The Indian Pharmaceutical Alliance welcomed an interim trade agreement between India and the US, emphasizing that medicine security is crucial for national security. The pact aims to boost bilateral trade by reducing import duties on various goods, including generics, and offers Indian MedTech exporters a competitive edge in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Z7RWUdD
via IFTTT

Read More

Wipro seeks Schedule M exemption for Tumkur plant, regulator to review plea

Wipro has sought relaxation in requirement of Schedule M for specific categories like disinfectants. The product, Maxkleen, has been registered as a drug. The company has asked to allow them to manufacture the product without a drug licence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VwMJ1gW
via IFTTT

Read More

Shukra Pharma gets YEIDA LoI for Rs 600-crore facility

Shukra Pharmaceuticals will establish a Rs 600-crore facility in Greater Noida. This plant will produce advanced surgical robotics and BNCT technology. The project aims to create over 900 direct jobs. A partnership with Borns Medical Robotics Inc. will bring surgical robotics to India. This venture seeks to make high-precision surgery affordable and accessible across India and Asia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SphfEqT
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets

Alembic Pharmaceuticals has secured a significant approval from the US health regulator. The company's generic version of Carbidopa, Levodopa, and Entacapone tablets, used for Parkinson's disease, has been cleared by the USFDA. This development marks a crucial step for Alembic in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qLcCkGV
via IFTTT

Read More

Drug regulator steps up oversight on product changes after approval

Drug makers now need government approval for any quality changes to medicines. This applies to alterations affecting a drug's identity, strength, quality, purity, or potency. The regulator is strengthening manufacturing standards through risk-based audits and more inspections. This ensures only safe and effective medicines reach consumers. Manufacturers must inform the drug regulator about changes in manufacturing, packaging, or shelf life.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Zi7GST3
via IFTTT

Read More

Sun Pharma to pump in Rs 500 cr in Assam manufacturing unit

Sun Pharmaceutical will invest Rs 500 crore to establish a new manufacturing plant in Assam. This significant project will create over 500 direct employment opportunities. The company plans to implement the investment in two phases. Discussions covered land, water, power, and skilled manpower. Sun Pharmaceutical will focus on sustainable manufacturing practices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dGMXqcE
via IFTTT

Read More

Biopharma Shakti: India targets China dependence, patent cliff

India is launching a major initiative to boost its biopharmaceutical manufacturing. This plan aims to reduce reliance on China for crucial drug components. It also seeks to capitalize on upcoming patent expirations of major global drugs. India will focus on becoming a hub for biosimilars and emerging biologics. This strategy will strengthen the nation's pharmaceutical industry on the global stage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pRPewuC
via IFTTT

Read More

AstraZeneca gets CDSCO approval for Durvalumab in gastric cancer treatment

AstraZeneca Pharma India has secured approval for Durvalumab. This drug, combined with chemotherapy, will treat gastric and gastroesophageal junction cancer. The approval comes from the Central Drugs Standard Control Organisation. This new treatment offers a perioperative immunotherapy approach for adult patients. It aims to improve survival rates for those with resectable forms of the disease.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4xou9T2
via IFTTT

Read More

Medical gear firms told to 'promptly' flag adverse cases

Indian medical device firms must now promptly report all adverse events, both serious and non-serious, to the government's Materiovigilance Programme. This directive aims to boost patient safety and address concerns over underreporting of issues linked to locally manufactured equipment. Timely reporting is crucial for identifying risks and implementing necessary safety measures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2hCVEeT
via IFTTT

Read More

US tariff cut to 18% to boost India’s medical device exports

India's medical device exports to the US will surge following a tariff cut. This move makes Indian products more competitive against China. Lower import duties will also benefit India's healthcare system by reducing costs for high-value equipment. Industry leaders hail the deal as transformative, unlocking significant market potential and fostering investment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TvIA4rh
via IFTTT

Read More

Budget relief on the label: Govt proposes to drop duty on rare disease drugs

The Indian budget proposes exempting seven rare disease drugs from import duties. This move aims to lower costs for expensive life-saving medicines. Patient groups welcome the relief for out-of-pocket expenses. However, some believe duty cuts alone will not make these drugs affordable for most Indians. The proposal also includes duty waivers on anti-cancer drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g10ExeW
via IFTTT

Read More

Lupin rolls out generic oncology drug in US market

Drug firm Lupin has launched a generic cancer treatment medication in the US. The company introduced Dasatinib Tablets in various strengths. This product is bioequivalent to Sprycel Tablets. It is indicated for adults with Philadelphia chromosome-positive chronic myeloid leukemia. The US market for Dasatinib Tablets had significant sales.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WhdD0eY
via IFTTT

Read More

Budget 2026 gives biologics & biosimilars a major policy boost

India is set to become a global biopharmaceutical manufacturing hub. Finance Minister Nirmala Sitharaman announced a dedicated ₹10,000 crore program over five years. This initiative focuses on biosimilars and biologics, crucial for treating non-communicable diseases. The move aims to boost manufacturing, regulation, and clinical trials, positioning India for future global competition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O5kjGqs
via IFTTT

Read More